-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, September 30, 2021/PRNewswire/ - Luye Pharmaceutical Group announced that its self-developed Class 1 new drug LY03015 has been approved by the Drug Evaluation Center of China National Medical Products Administration for clinical trials
LY03015 is used to treat tardive dyskinesia (Tardive Dyskinesia, TD) and Huntington's disease (Huntington's Disease, HD)
In the treatment of TD and HD, VMAT2 inhibitors are currently the only drug with proven clinical efficacy and safety
As a new generation of VMAT2 inhibitor, LY03015 can inhibit the release of dopamine (DA) in presynaptic neurons, avoiding DA's stimulation of hypersensitive D2 receptors while not blocking the D2 receptors of the postsynaptic membrane, thereby reducing TD , Symptoms of HD
In the future, based on further verification of product characteristics in clinical trials, LY03015 is expected to improve the clinical pain points of commercially available VMAT2 inhibitor drugs in terms of activity, efficacy, and safety, and has a broad market prospect
The central nervous system treatment field where LY03015 is located is one of the core strategic areas of Luye Pharma’s long-term deployment.
In January of this year, Rexinto® (Risperidone Microspheres for Injection (II)) for the treatment of schizophrenia was approved for marketing in China.
In addition to products already on the market, Luye Pharma has a number of new drugs under development that have entered the late-stage clinical and New Drug Application (NDA) stages in China, the United States and other markets, covering a variety of diseases such as depression and Parkinson's disease, forming in the central nervous system treatment field.
About Luye Pharmaceutical Group
Luye Pharmaceutical Group (Luye Pharmaceutical) is an international pharmaceutical company dedicated to the development, production and sales of innovative drugs
Luye Pharma has a deep layout of the global supply chain system.
Source: Luye Pharma
